ArticleBMJ (Clinical research ed.)2022
Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019.
Article in BMJ (Clinical research ed.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 543 papers, 15 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
543 citing papers in PubMed, 15 syntheses or guidelines pooled it.
- Patients' experiences of promoting and hindering factors in daily physical activity with chronic obstructive pulmonary disease: a qualitative systematic review.BMC pulmonary medicine · 2026Pooled it
- Comparative effectiveness of triple versus dual inhaled therapy (ICS/LABA or LABA/LAMA) for chronic obstructive pulmonary disease: a systematic review and network meta-analysis.BMC pulmonary medicine · 2026Pooled it
- High-Flow Nasal Cannula Versus Noninvasive Ventilation in the Treatment of Hypercapnic Respiratory Failure: Meta-Analysis of Randomized Controlled Trials.Journal of evidence-based medicine · 2026Pooled it
- Public health challenges of climate change-induced non-communicable diseases in vulnerable populations and resource-limited healthcare system: a systematic review.BMC public health · 2026Pooled it
- Statins for the prevention of exacerbations in COPD: a systematic review and meta-analysis of randomized controlled trials.Systematic reviews · 2026Pooled it
- Prevalence of COPD in other long-term conditions: a systematic meta review.BMC pulmonary medicine · 2026Pooled it
- Efficacy and safety of different inhaler types for asthma and chronic obstructive pulmonary disease. a systematic review and meta-analysis.NPJ primary care respiratory medicine · 2026Pooled it
- Burden of chronic obstructive pulmonary disease among Indian adults: systematic review and meta‑analysis.BMC pulmonary medicine · 2026Pooled it
- Global herpes zoster burden in adults with COPD: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Anti-type 2 monoclonal antibody therapy for eosinophilic COPD beyond triple therapy: a systematic review and meta-analysis with strict eosinophil inclusion criteria.Frontiers in medicine · 2026Pooled it
- The Relationship Between Gas Transfer Measurements, Lung Volumes, and Spirometric Indices in Alpha-1 Antitrypsin Deficiency and Non-AATD COPD: A Systematic Review.International journal of chronic obstructive pulmonary disease · 2026Pooled it
- The Effectiveness of Respiratory Muscle Training on the Duration and Severity of Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.Canadian respiratory journal · 2026Pooled it
- Lung function improvement following smoking cessation in chronic respiratory conditions: A meta-analytic approach.The Journal of international medical research · 2025Pooled it
- Effectiveness of Nurse Led Advance Care Planning Intervention for Chronic Respiratory Diseases: A Meta-Analysis.Nursing open · 2025Pooled it
- Ambient air pollution exposure, mediating biomarkers and risk of COPD: a cohort study and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials.American journal of respiratory and critical care medicine · 2026Trial
- Visual feedback using electrical impedance tomography during inhalation therapy for chronic obstructive lung disease: a pilot study.Scientific reports · 2026Trial
- Development of a clinical prediction model for falls in individuals with COPD.BMJ open respiratory research · 2025Trial
- Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE.Journal of the American Heart Association · 2025Trial
- A pilot randomised controlled trial of the Tailored Intervention for people with moderate-to-severe Chronic Obstructive Pulmonary Disease and Co-morbidities delivered by Pharmacists and Consultant respiratory Physicians (TICC-PCP).NPJ primary care respiratory medicine · 2025Trial
483 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo report the global, regional, and national burden of chronic obstructive pulmonary disease (COPD) and its attributable risk factors between 1990 and 2019, by age, sex, and sociodemographic index.
designSystematic analysis. DATA SOURCE: Global Burden of Disease Study 2019.
main outcome measuresData on the prevalence, deaths, and disability adjusted life years (DALYs) of COPD, and its attributable risk factors, were retrieved from the Global Burden of Disease 2019 project for 204 countries and territories, between 1990 and 2019. The counts and rates per 100 000 population, along with 95% uncertainty intervals, were presented for each estimate.
resultsIn 2019, 212.3 million prevalent cases of COPD were reported globally, with COPD accounting for 3.3 million deaths and 74.4 million DALYs. The global age standardised point prevalence, death, and DALY rates for COPD were 2638.2 (95% uncertainty intervals 2492.2 to 2796.1), 42.5 (37.6 to 46.3), and 926.1 (848.8 to 997.7) per 100 000 population, which were 8.7%, 41.7%, and 39.8% lower than in 1990, respectively. In 2019, Denmark (4299.5), Myanmar (3963.7), and Belgium (3927.7) had the highest age standardised point prevalence of COPD. Egypt (62.0%), Georgia (54.9%), and Nicaragua (51.6%) showed the largest increases in age standardised point prevalence across the study period. In 2019, Nepal (182.5) and Japan (7.4) had the highest and lowest age standardised death rates per 100 000, respectively, and Nepal (3318.4) and Barbados (177.7) had the highest and lowest age standardised DALY rates per 100 000, respectively. In men, the global DALY rate of COPD increased up to age 85-89 years and then decreased with advancing age, whereas for women the rate increased up to the oldest age group (≥95 years). Regionally, an overall reversed V shaped association was found between sociodemographic index and the age standardised DALY rate of COPD. Factors contributing most to the DALYs rates for COPD were smoking (46.0%), pollution from ambient particulate matter (20.7%), and occupational exposure to particulate matter, gases, and fumes (15.6%).
conclusionsDespite the decreasing burden of COPD, this disease remains a major public health problem, especially in countries with a low sociodemographic index. Preventive programmes should focus on smoking cessation, improving air quality, and reducing occupational exposures to further reduce the burden of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.